Quanterix Appoints Dr. Yuri Fesko as Chief Medical Officer to Advance Diagnostics Strategy
Quanterix Corporation, a global leader in precision biomarker science, has announced the appointment of physician executive Dr. Yuri Fesko as its new Chief Medical Officer. The appointment adds significant medical, clinical development and precision diagnostics expertise to Quanterix as the company prepares to expand its diagnostics business and advance several key technology and product initiatives.
In his new role, Dr. Fesko will provide medical and clinical leadership across the organization. He will work closely with Quanterix’s Diagnostics, Scientific, Research and Development, Regulatory, and Commercial teams to support the development, validation and expansion of the company’s diagnostic technologies and their applications in clinical medicine.
The appointment comes at an important stage in Quanterix’s growth, particularly as the company prepares for the broader market launch of its Lucent AD® Complete five-biomarker test for Alzheimer’s disease. The company is also progressing toward an in vitro diagnostic (IVD) filing for its HD-X instrument, making medical and regulatory expertise increasingly important to its strategy.
Everett Cunningham, President and Chief Executive Officer of Quanterix, said Dr. Fesko’s experience will strengthen the company’s efforts to scale its diagnostics operations and expand the clinical applications of its technologies.
“As we prepare for the broader market launch of our Lucent AD Complete five biomarker test for Alzheimer’s Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expansion in diagnostics,” Cunningham said.
He added that Fesko’s background in clinical affairs at a major diagnostics company, combined with his experience in precision medicine, will be particularly valuable as Quanterix accelerates the commercialization of Lucent AD Complete and works toward the IVD filing for its HD-X platform.
According to Cunningham, Fesko’s ability to operate across medicine, diagnostics, analytics and business strategy will also support Quanterix as it continues to develop its Diagnostics business and broaden the clinical impact of its biomarker technologies.
Leadership Experience at Quest Diagnostics
Fesko joins Quanterix following his most recent position as Chief Medical Officer at Quest Diagnostics, where he held responsibility for several areas spanning Medical Affairs, Clinical Development, Analytics and Public Health. His work involved providing medical and analytical leadership across the organization and supporting the integration of clinical expertise into business and diagnostic initiatives.
At Quest Diagnostics, Fesko also served as a medical leader supporting Quality and Regulatory functions. His responsibilities included providing senior-level medical leadership for pathology and dermatopathology, giving him experience across both clinical and operational aspects of a large-scale diagnostics organization.
His background is particularly relevant to Quanterix as the company continues to transition its precision biomarker technologies into applications that can support clinical decision-making. Modern diagnostic development increasingly requires coordination between scientific discovery, analytical performance, clinical validation, regulatory requirements and commercialization. Fesko’s experience across these areas is expected to help Quanterix navigate this intersection as it expands its diagnostic portfolio.
Focus on Precision Medicine and Advanced Diagnostics
Throughout his career, Fesko has developed extensive expertise in precision medicine and the use of advanced diagnostic technologies to support individualized approaches to patient care. His experience spans multiple therapeutic and healthcare areas, including oncology, metabolic disease, neurology and consumer health.
Precision diagnostics are becoming increasingly important as healthcare moves toward more targeted approaches to disease detection, risk assessment, treatment selection and patient monitoring. Biomarker technologies can play an important role in this transition by providing clinicians and researchers with quantitative information that may help characterize disease and inform clinical decisions.
Fesko has worked with health systems, pharmaceutical and biotechnology companies, and physician organizations to support the integration of precision diagnostics into clinical practice and clinical trials. This experience provides a broad perspective on how diagnostic technologies need to fit within healthcare workflows and how their clinical utility can be demonstrated to physicians, healthcare organizations and other stakeholders.
His industry background also includes experience with regulatory and clinical development activities for advanced diagnostic technologies. Fesko has supported FDA submissions and clinical development programs, as well as companion diagnostic strategies and reimbursement planning. These areas are critical for companies seeking to move diagnostic innovations from research environments into routine clinical use.
Lucent AD Complete Represents a Key Commercial Opportunity
One of the immediate priorities associated with Fesko’s appointment is expected to be Quanterix’s broader market launch of Lucent AD Complete, the company’s five-biomarker test for Alzheimer’s disease.
Alzheimer’s disease diagnostics have become an increasingly important area of development as researchers and healthcare providers seek more accessible and scalable approaches to identifying disease-related biological changes. Biomarker testing can complement traditional clinical assessments and imaging approaches by providing additional biological information.
For Quanterix, the planned expansion of Lucent AD Complete represents an important opportunity to apply its precision biomarker capabilities to a major area of unmet medical need. The company’s broader strategy is focused on using highly sensitive biomarker technologies to support applications across neurological disease and other areas of medicine.
Fesko’s experience in neurology, precision medicine, clinical affairs and diagnostics could therefore be particularly relevant as Quanterix works to expand the clinical and commercial reach of its Alzheimer’s disease testing capabilities.
Advancing the HD-X IVD Strategy
In addition to supporting the Lucent AD Complete launch, Fesko will contribute to Quanterix’s efforts to advance an IVD filing for the company’s HD-X instrument.
The HD-X platform is part of Quanterix’s technology portfolio for highly sensitive biomarker analysis. Advancing an instrument and associated diagnostic applications toward regulatory submission requires coordination across scientific development, clinical evidence generation, quality systems, regulatory strategy and commercial planning.
Fesko’s previous experience supporting FDA submissions and working with Quality and Regulatory organizations positions him to contribute to these efforts. His involvement is expected to help connect clinical considerations with the company’s regulatory and development priorities as Quanterix progresses its diagnostics strategy.
Expanding the Clinical Impact of Biomarker Science
Quanterix has built its business around precision biomarker science and technologies designed to enable highly sensitive detection and measurement of biological markers. The company’s platforms have applications across research, drug development and diagnostics.
The appointment of a Chief Medical Officer with experience spanning diagnostics, clinical development and precision medicine reflects the company’s continued focus on expanding the clinical applications of its technology.
As biomarker science continues to develop, companies operating in the field increasingly need to demonstrate not only analytical performance but also clinical relevance and practical utility. Establishing connections between biomarker measurements and patient outcomes, clinical decisions and healthcare economics can be important to successful adoption.
Fesko’s experience working with health systems, pharmaceutical and biotechnology companies and physician groups gives him exposure to the different stakeholders involved in bringing advanced diagnostics into healthcare. His background may also help Quanterix strengthen relationships between its scientific capabilities and the needs of clinicians and patients.
Broad Medical and Clinical Expertise
Fesko brings a multidisciplinary background to the role. His experience includes medical affairs, clinical development, analytics, public health, pathology, regulatory support and precision medicine.
His work across oncology, metabolic disease, neurology and consumer health also provides exposure to a wide range of diagnostic applications and patient populations. This breadth may be useful as Quanterix evaluates opportunities to expand its technology beyond individual products and into additional areas of clinical medicine.
The company expects his leadership to complement its existing scientific and commercial capabilities while helping align medical priorities across different functions.
Education and Medical Training
Fesko earned both his Bachelor’s degree and Doctor of Medicine degree from Case Western Reserve University. He subsequently completed a fellowship at University Hospitals of Cleveland.
He is board-certified in Internal Medicine, Hematology and Medical Oncology, reflecting extensive clinical training and specialization in areas where biomarkers and precision medicine have become increasingly important to patient management and therapeutic development.
Fesko will be based at Quanterix’s headquarters in Billerica, Massachusetts, where he will work with the company’s teams as it advances its diagnostics and broader biomarker strategy.
Strategic Significance for Quanterix
The appointment comes as Quanterix seeks to strengthen its position at the intersection of biomarker science, diagnostics and precision medicine. With the anticipated broader launch of Lucent AD Complete and continued work toward an IVD filing for the HD-X instrument, the company is entering a period in which clinical, regulatory and commercial execution will be increasingly important.
By adding Fesko to its leadership team, Quanterix gains an executive with experience operating within a major diagnostics organization and working across clinical development, regulatory affairs, analytics and precision medicine.
His appointment is expected to support the company’s efforts to translate its biomarker technologies into broader clinical applications. It also underscores Quanterix’s focus on developing diagnostic solutions that can potentially contribute to earlier and more informed disease assessment.
As the company advances its Alzheimer’s disease testing program and works toward additional diagnostic milestones, Fesko’s medical and clinical expertise is positioned to play an important role in guiding Quanterix’s next stage of growth.
About Quanterix
Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics.